(Bloomberg) — Should patients undergoing broad DNA testing for a specific ailment be told of unexpected findings that signal risk of cancer or other serious diseases, even if they don’t request the information?
The question is at the core of a battle brewing among doctors and ethicists amid growing use of gene sequencing for clinical use and the plethora of information that results from such tests. Writing in the journal Science, a team of ethicists say patients should decide how much they want to know and how deeply scientists should look into their genome.
